This Fund Just Disclosed a New $55 Million Bet on Centessa Amid 53% Stock Rally and CEO Transition

Company Overview - Centessa Pharmaceuticals is a clinical-stage biotechnology company based in the United Kingdom, focusing on a diversified pipeline across nephrology, hematology, immunology, and rare diseases [6] - The company emphasizes rapid clinical development and aims to provide first-in-class therapies to meet significant unmet medical needs in specialty care markets [6] - As of February 17, 2026, Centessa's market capitalization is $3.37 billion, with a revenue of $15 million and a net income of -$242.7 million [4] Recent Developments - On February 17, 2026, Braidwell disclosed a new position in Centessa, acquiring 2,188,320 shares valued at approximately $54.73 million [1][2] - This new stake represents 1.75% of Braidwell's 13F reportable assets under management [8] - Centessa's stock price reached $24.94, reflecting a 53.4% increase over the past year, significantly outperforming the S&P 500 by 34.19 percentage points [8] Pipeline and Strategy - Centessa is advancing multiple drug candidates, including Lixivaptan (Phase III for polycystic kidney disease) and SerpinPC (Phase IIa for hemophilia), along with therapies targeting rare diseases and autoimmune disorders [9] - The company operates a research-driven model focused on drug discovery and development, aiming for successful drug approvals and commercialization [9] - A strategic shift towards orexin agonists has been initiated, with Mario Accardi appointed as CEO to lead this focus [10] Market Position and Future Outlook - The recent preclinical data supports the expansion of Centessa's focus beyond rare hypersomnias into neuropsychiatric indications, including depressive disorders [11] - The new stake by Braidwell indicates a measured approach to investing in Centessa, reflecting confidence in the potential of orexin agonists to address various high-value indications [12] - Despite the volatility in clinical-stage neuroscience, the position sizing suggests a disciplined investment strategy [12]